Biohaven Ltd. Common Shares (BHVN) closed at $12.39 on November 20, 2026, down 9.2% from the previous close, on volume of 2,196,541 shares (30-day average 3,067,664).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 20, 2026 | Calendar Put Spread | 20-Nov : 18-Dec-26 15 P | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 20-Nov 5:30 AM ET)
Biohaven rises after early-stage trial data for cancer therapy
Seeking Alpha News (Thu, 19-Nov 2:14 PM ET)
PRNewswire (Thu, 19-Nov 7:30 AM ET)
Biohaven Presents Development Programs at Jefferies Healthcare Conference
TipRanks (Mon, 16-Nov 7:04 AM ET)
PRNewswire (Thu, 5-Nov 7:30 AM ET)
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
PRNewswire (Thu, 29-Oct 4:03 PM ET)
PRNewswire (Mon, 26-Oct 7:31 AM ET)
Market Chameleon (Thu, 8-Oct 3:06 AM ET)
PRNewswire (Thu, 8-Oct 4:01 AM ET)
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.
As of November 20, 2026, BHVN stock price declined to $12.39 with 2,196,541 million shares trading.
BHVN has a beta of 1.28, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.07 to the broad based SPY ETF.
BHVN has a market cap of $1.87 billion. This is considered a Small Cap stock.
Last quarter Biohaven Ltd. Common Shares reported $0 in Revenue and -$.73 earnings per share. This fell short of revenue expectation by $-110 million and missed earnings estimates by -$.70.
In the last 3 years, BHVN traded as high as $62.21 and as low as $7.48.
The top ETF exchange traded funds that BHVN belongs to (by Net Assets): XBI, IWM, VXF, IWO, IBB.
BHVN has outperformed the market in the last year with a return of +28.7%, while the SPY ETF gained +6.9%. In the last 3 month period, BHVN beat the market returning -8.2%, while SPY returned -9.3%. However, in the most recent 2 weeks BHVN has underperformed the stock market by returning -14.4%, while SPY returned -6.2%.
BHVN support price is $12.98 and resistance is $14.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.